Aegera Therapeautics Completes Second Tranche Draw-down

On October 31, 2003, biotechnology company Aegera Therapeutics Inc., completed the draw-down of a second tranche of $4.025 million of investment under its December 13, 2001 subscription agreement. The investors participating in the second tranche draw-down included GeneChem Therapeutics Venture Fund LP, the Fonds de solidaritié des travailleurs du Québec 9FTQ), the Business Development Bank of Canada, T2C2/Bio 2000, Societe en commandite, ID Limited Partnership, Capital régional et coopératif Desjardins, Capital Technologies CDPQ Inc., Societé Innovatech du Grand Montreal Canadian Medical Discoveries Fund Inc., and NeuroScience Partners Limited Partnership. Aegera and the investors were represented by Sharon Druker of Gowling LaFleur Henderson LLP in Montreal.